Pharmaceutical Research Transparency Act of 2023

The Pharmaceutical Research Transparency Act of 2023, also known as Bill 118 hr 3160, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to increase transparency in the pharmaceutical industry by requiring drug companies to disclose more information about their research and development processes.

Under this bill, pharmaceutical companies would be required to provide detailed information about the clinical trials they conduct, including the results of those trials and any adverse effects experienced by participants. This information would be made publicly available on a centralized database, allowing researchers, healthcare providers, and the general public to access and analyze it.

Additionally, the Pharmaceutical Research Transparency Act of 2023 aims to address concerns about conflicts of interest in the pharmaceutical industry by requiring companies to disclose any financial relationships they have with healthcare providers, researchers, or patient advocacy groups. This information would also be made publicly available to ensure transparency and accountability. Overall, the goal of this bill is to promote transparency and accountability in the pharmaceutical industry, ultimately leading to better-informed decision-making by healthcare providers and patients. It is currently being debated in Congress, with supporters arguing that it will help to improve the safety and effectiveness of drugs, while opponents raise concerns about the potential impact on innovation and drug development.